Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hawlik K, Wild C. Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Decision Support Document. 2017 Authors' objectives Extracorporeal cytokine adsorption therapy (ECAT) aims to reduce the cytokine concentration in the blood, thereby stabilising the overall immune response in sepsis and SIRS (Systemic Inflammatory Response Syndrome). We investigated the efficacy and safety of ECAT in its two main indications: to treat sepsis and to prevent SIRS during cardiopulmonary bypass surgery (CPB). Authors' conclusions Overall, three studies were identified that contained clinical data on ECAT. However, no data for the assessment of ECAT in patients with sepsis and septic shock were available. The overall quality of the studies on the preventive use during CPB was classified as very low. No conclusions could be drawn as to whether ECAT is a safe and effective intervention. We therefore do not recommend inclusion of ECAT in the Austrian BMG benefit catalogue and suggest a re-evaluation should randomised controlled trials in both indications become available. Indexing Status Subject indexing assigned by CRD MeSH Cytokines; Hemadsorption; Humans; Sepsis; Systemic Inflammatory Response Syndrome Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000336 Date abstract record published 01/08/2017 |